Open AccessExpression of RET finger protein predicts chemoresistance in epithelial ovarian cancer
Author(s) -
Horio Maiko,
Kato Takuya,
Mii Shinji,
Enomoto Atsushi,
Asai Masato,
Asai Naoya,
Murakumo Yoshiki,
Shibata Kiyosumi,
Kikkawa Fumitaka,
Takahashi Masahide
Publication year - 2012
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.32
Subject(s) - ovarian cancer , carboplatin , paclitaxel , gene knockdown , taxane , cancer research , cancer , drug resistance , rna interference , medicine , apoptosis , chemotherapy , predictive marker , biology , oncology , breast cancer , cisplatin , gene , rna , biochemistry , microbiology and biotechnology
Resistance to platinum‐ and taxane‐based chemotherapy is a major cause of treatment failure in ovarian cancer. Thus, it is necessary to develop a predictive marker and molecular target for overcoming drug resistance in ovarian cancer treatment. In a previous report, using an in vitro model, we found that the RET finger protein ( RFP ) (also known as tripartite motif‐containing protein 27, TRIM 27) confers cancer cell resistance to anticancer drugs. However, the significance of RFP expression in cancer patients remains elusive. In this study, we showed that RFP was expressed in 62% of ovarian cancer patients and its positivity significantly correlated with drug resistance. Consistent with clinical data, depletion of RFP by RNA interference ( RNAi ) in ovarian cancer cell lines, SKOV 3 and HEY , significantly increased carboplatin‐ or paclitaxel‐induced apoptosis and resulted in reduced anticancer drug resistance. In a nude mouse tumor xenograft model, inoculated RFP ‐knockdown ovarian cancer cells exhibited lower carboplatin resistance than control cells. These findings suggest that RFP could be a predictive marker for chemoresistance in ovarian cancer patients and also a candidate for a molecular‐targeted agent.